Differences in outcome due to bevacizumab (BEV) discontinuation versus BEV failure in adults with glioblastoma.
Mark Daniel Anderson
No relevant relationships to disclose
Vinay K. Puduvalli
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Bayer; Celgene; Genentech; Merck
Mohamed Ali Hamza
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - Abbott Laboratories; Genentech; Merck
Honoraria - Genentech; Merck
Research Funding - Genentech; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck
Honoraria - Actelion; Merck; Novartis
Research Funding - Daiichi Sankyo; Novartis